AI-generated · cited to primary sources · not investment advice · How we research
Johnson & Johnson Common Stock
Our verdict on Johnson & Johnson Common Stock isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company maintained its dividend commitment, paying $1.30 per share in Q3 2025 and declaring an identical amount for Q4 2025. (1 met across 1 tracked commitment)
“On July 16, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share... The Company expects to continue the practice of paying regular quarterly cash dividends.”
The impact of biosimilar competition for STELARA is now clearly visible in the financials, causing a 6.1% drag on worldwide operational sales growth in the first nine months of 2025. (1 met across 1 tracked commitment)
“The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA.”
See the full cited Management analysis of Johnson & Johnson Common Stock
How durable is the business?
Profitability in the pharmaceutical segment improved significantly, with margins expanding from 35.0% to 38.6%. This was driven by lower R&D spending as a percentage of sales and the absence of large one-time acquisition charges seen in the prior year. (2 expanding across 1 engine)
“Innovative Medicine segment sales in the fiscal first quarter of 2026 were $15.4 billion, an increase of 11.2%... segment income before tax as a percent of sales... was 34.5%”
The segment remains the primary revenue engine, growing to a 64.0% share of total sales. Growth was driven by Oncology (up 21.1%) and Neuroscience (up 3.2%), though partially offset by a significant decline in Stelara sales due to biosimilar competition. (5 expanding across 1 engine)
“MedTech segment sales in the fiscal first quarter of 2026 were $8.6 billion, an increase of 7.7%... segment income before tax as a percent of sales... was 14.3%”
See the full cited Business Model analysis of Johnson & Johnson Common Stock
Where does growth come from?
The Cardiovascular franchise is showing significant acceleration, with operational growth jumping to 17.7% this quarter, largely driven by the acquisition of Shockwave Medical and strong adoption of Abiomed's Impella products. (5 accelerating across 5 signals, 1 leading indicator)
“Innovative Medicine segment sales in the fiscal first quarter of 2026 were $15.4 billion, an increase of 11.2% as compared to the same period a year ago”
The Cardiovascular franchise is accelerating significantly, driven by the acquisition of Shockwave and strong performance in Electrophysiology, which grew 16.5% operationally in the first nine months. (1 accelerating, 2 new trend, 2 steady across 5 signals, 2 leading indicators)
“In October 2025, the Company announced its intention to separate its Orthopaedics business... with a targeted completion within 18 to 24 months after the initial announcement.”
See the full cited Future Growth analysis of Johnson & Johnson Common Stock
What could break the thesis?
The risk is easing financially as the company reversed approximately $7.0 billion of its talc reserve following a bankruptcy court dismissal, though it remains in the tort system to litigate remaining claims. (2 easing, 2 stable, 1 intensifying, 2 high-severity)
“As of March 29, 2026, there are approximately 75,000 plaintiffs in the United States with direct claims against the Company... the total present value of the reserve for talc related matters is approximately $3.4 billion”
The risk is intensifying as biosimilar competition is now materially impacting sales, causing a 39.5% decline in STELARA revenue for the first nine months of 2025. (2 intensifying, 1 stable, 1 high-severity)
“In the fiscal first quarter of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.4%.”
See the full cited Risk analysis of Johnson & Johnson Common Stock
Read the full thesis on Johnson & Johnson Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.